Sign in to continue:

Friday, March 6th, 2026

Public Disclosure of Securities Dealings by UBS AG in ENN Energy Holdings Limited Shares Amid Privatisation Scheme (March 2026)

Key Points for Investors

  • Large Share Transactions:

    • On March 3, 2026, UBS AG purchased 271,226 ordinary shares of ENN Energy Holdings Limited for a total amount of \$19,220,048.89. The highest price paid was \$71.2840 and the lowest was \$70.4250.
    • This purchase was executed as part of hedging Delta 1 products, which were created in response to wholly unsolicited, client-driven orders.
  • Client Facilitation Desk Activity:

    • UBS AG sold 700 ordinary shares for \$49,985.00. The highest sale price was \$71.8500, and the lowest was \$71.2000.
    • These trades arose from unsolicited client-driven orders by a client facilitation desk operating independently from the proprietary trading desk. Any resultant proprietary positions will be flattened no later than the close of the morning trading session the next trading day.
  • ETF Redemption:

    • UBS AG also purchased 100 ordinary shares for \$7,185.00 as a result of redemption of pre-existing index-tracking ETFs, again driven by unsolicited client requests. All shares were bought at \$71.8500.

Important Information for Shareholders

  • Privatisation Context: The disclosure is made in connection with ENN Energy’s proposed privatisation, which is a significant corporate event. Any substantial trading activity, especially by an exempt principal trader like UBS AG, can signal market sentiment or anticipation of changes in the share price.
  • Price Sensitivity: The volume and nature of these transactions – especially the large purchase for hedging purposes and ETF redemption – may reflect heightened investor activity surrounding the privatisation scheme. The prices paid and received (\$70.4250 to \$71.8500) provide a recent trading range that may be of interest to shareholders, especially in the context of the privatisation.
  • UBS AG’s Role: UBS AG is an exempt principal trader connected with ENN Energy Holdings Limited and is ultimately owned by UBS Group AG. All disclosed dealings were made for UBS AG’s own account.
  • Potential Market Impact: Significant trading activities by a major financial institution in the context of a privatisation scheme can influence the share price, either through direct market impact or as a signal to other market participants.

Investor Takeaways

The disclosed dealings by UBS AG highlight increased trading activity in ENN Energy Holdings Limited shares at prices closely aligned with the current market levels. Investors should take note of the privatisation context and the role of UBS AG as an exempt principal trader, as this may influence both market perception and actual share price movements in the near term.


Disclaimer: This article summarizes public disclosures made by UBS AG regarding its dealings in ENN Energy Holdings Limited shares. It does not constitute financial advice. Investors should conduct their own research and consult professional advisors before making any investment decisions.

View ENN ENERGY Historical chart here



Abbisko Therapeutics Begins Phase I/II Clinical Trial of Oral KRAS G12D Inhibitor ABSK141 for Advanced Solid Tumors 12

Abbisko Therapeutics Announces First Patient Dosing in KRAS G12D Clinical Trial: Key Details for Investors Abbisko Therapeutics Completes First Patient Dosing in KRAS G12D Phase I/II Clinical Trial Summary of Key Points First patient...

XD Inc. Expects 77% Net Profit Growth and 13.9% Revenue Increase in 2025 Positive Profit Alert 1

XD Inc. Issues Positive Profit Alert: Strong Revenue and Profit Growth Expected for FY2025 XD Inc. (Stock Code: 2400) has released a positive profit alert to its shareholders and potential investors, indicating a significant...

BlackRock Discloses Share Purchases in ENN Energy Holdings Amid 2026 Privatisation Scheme 1

BlackRock Increases Stake in ENN Energy Holdings Amid Privatisation Scheme BlackRock Increases Stake in ENN Energy Holdings Amid Privatisation Scheme Key Points from Public Disclosure Date of Disclosure: 17 February 2026 Event: Disclosure of...

   Ad